Adipotide
Adipotide (FTPP)
Adipotide (FTPP) is a peptidomimetic compound designed to selectively destroy blood vessels supplying white adipose tissue by targeting the prohibitin receptor on the vasculature of fat cells, leading to apoptosis of adipocytes. It was developed as an experimental anti-obesity agent and has demonstrated significant fat loss in preclinical primate and rodent models without requiring caloric restriction. It remains strictly a research compound with no approved human clinical applications.
Mechanism of Action
Adipotide is a chimeric peptide consisting of a targeting domain (CKGGRAKDC) that binds prohibitin on the surface of white adipose tissue vasculature, fused to a pro-apoptotic domain (KLAKLAK)2 that disrupts mitochondrial membranes upon internalization. This dual-domain structure causes selective apoptosis of the endothelial cells feeding adipose deposits, cutting off nutrient supply and triggering adipocyte cell death. The process results in rapid reduction of fat mass, particularly visceral and subcutaneous adipose tissue, mediated by targeted vascular pruning rather than systemic metabolic effects.
Evidence by Health Goal(7 goals)
Dosing Protocols
Morning, subcutaneous injection into abdominal region or alternating sites
Cycle: 4-6 weeks on, 8-12 weeks off minimum
Dosing is extrapolated from primate studies (approximately 0.5-1mg/kg bodyweight in animals); human dosing protocols are entirely empirical with no validated clinical data. Aggressive hydration (3+ liters/day) is strongly advised due to nephrotoxic risk. Lower end doses are strongly recommended for initial use.
Safety & Side Effects
Adipotide carries a significant safety concern due to demonstrated nephrotoxicity in rhesus monkey studies, which caused reversible but measurable kidney damage even at therapeutic doses; this is not a well-tolerated research compound. It is not approved for human use in any jurisdiction and is legal only as a research chemical in most countries, with human administration representing unquantified risk.
Possible Side Effects
- !Nephrotoxicity and acute kidney injury (most serious risk observed in primate studies)
- !Dehydration and electrolyte imbalance secondary to renal effects
- !Injection site reactions including pain, swelling, and local tissue irritation
- !Fatigue and general malaise during active dosing periods
- !Nausea and gastrointestinal discomfort
- !Potential off-target apoptosis in non-adipose vascular tissue at higher doses
- !Elevated serum creatinine and BUN indicative of renal stress
Interactions
- -Contraindicated with nephrotoxic drugs (NSAIDs, aminoglycosides, contrast agents) due to additive kidney damage risk
- -May potentiate hypotensive effects of antihypertensive medications due to rapid body composition changes
- -Caution with diuretics as concurrent use dramatically increases dehydration and electrolyte imbalance risk
- -May alter insulin sensitivity and glucose metabolism, requiring dose adjustment in diabetics using insulin or oral hypoglycemics
- -Concurrent use with other pro-apoptotic or vascular-targeting agents is contraindicated due to unknown additive toxicity
Cost & Where to Buy
Research-grade Adipotide is available from select peptide vendors at approximately $40-150 per vial (1-5mg); monthly cost depends heavily on dose used and vial concentration. Purity and authenticity vary widely between vendors, and there is no regulatory oversight of research peptide quality.
Search on Amazon